Gene-based polygenic risk scores analysis of alcohol use disorder in African Americans

Dongbing Lai1,2, Tae-Hwi Schwantes-An1, Marco Abreu1, Grace Chan2,3, Victor Hesselbrock2, Chella Kamarajan9, Yunlong Liu1, Jacquelyn L. Meyers4, John I. Nurnberger Jr1,5, Martin H. Plawecki5, Leah Wetherill4, John I. Nurnberger Jr2,3, Victor Hesselbrock2, Chella Kamarajan9 and Tatiana Foroud1

INTRODUCTION

Alcohol use disorder (AUD) is one of the most common public health problems [1] and both genetic and environmental factors contribute to risk. Estimates of the heritability of AUD range from 40% to 60% [2–4]. Recently, several large-scale genome-wide association studies (GWAS) of AUD-related phenotypes have reported many genetic variants associated with AUD [5–7]. These GWAS reiterated the highly polygenic underpinnings of AUD and related phenotypes where many variants contribute small effects on AUD. Consequently, polygenic risk scores (PRS) have proven to be a strong approach for assessing AUD genetic liability beyond the genome-wide significant variants [5, 7]. For instance, in our previous study of an European ancestry cohort [8], individuals comprising the top PRS decile were almost twice as likely to meet the criteria for AUD compared to all others, an estimate comparable to those published for the first-degree family history of AUD in national surveys [9, 10]. However, PRS analysis of AUD in admixed populations, such as African Americans (AA), suffer from poor performance due to the much smaller sample sizes of the discovery GWAS [5].

The performance of PRS relies on well-powered discovery GWAS to accurately select the disease-associated variants and estimate their effect sizes, and well-matched target datasets. For admixed populations, the sample sizes of the discovery GWAS comparable to European ancestry (EA) populations (hundreds of thousands to >1 million) require extensive and strategic data collection. Studies have shown that many disease-causing genes are shared among different populations [11–14]. Therefore, large-scale EA GWAS summary statistics can be leveraged to improve the performance of PRS in non-EA populations by increasing the overall discovery GWAS sample size. However, disease-associated variants may have different allele frequencies and effect sizes in different populations, and linkage disequilibrium (LD) patterns are also different [12, 15–18], i.e., the target datasets are not matched to the discovery GWAS. Furthermore, for admixed populations such as AA, the proportions of African ancestry range from close to 0 to almost 100% and are differently distributed across the genome, making AA an extremely heterogeneous population. Therefore, different AA target datasets may also have different LD patterns.
We compared the performance of PRSgene with PRS calculated using Gene Ontology (http://geneontology.org/) to test whether known disease genes in the genome that are unlikely to be related to a disease, thereby increasing the signal-to-noise ratio. Moreover, since these disease-causing variants are shared among different populations, the genome discovery GWAS and target datasets do not have to be well-matched and the large-scale EA GWAS can be used to increase the overall discovery GWAS sample size. Based on these observations, we propose a novel gene-based PRS framework aimed at enhancing the performance of PRS in admixed populations. We first used an AA GWAS and an EA GWAS to identify genes that were associated with AUD in both populations, then used variants located within these genes’ boundaries to calculate PRS (PRSgene). We compared the performance of PRSgene with PRS calculated using a family-based polygenic prediction in which related individuals may be repurposed to treat AUD.

METHODS

Discovery GWAS

The discovery GWAS were from the meta-GWAS of problematic alcohol use in EA cohorts (EA-PAU) (N = 435,563) [7] and the AA GWAS of AUD from the Million Veteran Program (AA-AUD) (N = 56,648) [5], the largest GWAS of AUD-related phenotypes to date in EA and AA populations, respectively. The EA-PAU was a meta-analysis of problematic alcohol use [7] comprised of the AUD-related phenotypes to date in EA and AA populations, respectively. The EA-PAU was diagnosed based on ICD9 (303 and 305.0) and ICD10 (F10) codes. The majority of variants in the genome are likely not related to a particular condition and including them in PRS calculations will likely to be a shared disease-causing variant and that gene is likely to be a shared disease-causing gene across populations.

Therefore, using these variants to calculate PRS is expected to improve the performance by excluding many variants in the genome that are unlikely to be related to a disease, thereby increasing the signal-to-noise ratio. Moreover, since these disease-causing variants are shared among different populations, the discovery GWAS and target datasets do not have to be well-matched and the large-scale EA GWAS can be used to increase the overall discovery GWAS sample size. Based on these observations, we propose a novel gene-based PRS framework aimed at enhancing the performance of PRS in admixed populations. We first used an AA GWAS and an EA GWAS to identify genes that were associated with AUD in both populations, then used variants located within these genes’ boundaries to calculate PRS (PRSgene). We compared the performance of PRSgene with PRS calculated using a family-based polygenic prediction in which related individuals may be repurposed to treat AUD.

Methods

Discovery GWAS

The discovery GWAS were from the meta-GWAS of problematic alcohol use in EA cohorts (EA-PAU) (N = 435,563) [7] and the AA GWAS of AUD from the Million Veteran Program (AA-AUD) (N = 56,648) [5], the largest GWAS of AUD-related phenotypes to date in EA and AA populations, respectively. The EA-PAU was a meta-analysis of problematic alcohol use [7] comprised of the AUD GWAS of the Million Veteran Program Phase I [5] and Phase II data, the alcohol dependence GWAS from the Psychiatric Genomics Consortium [25], and the GWAS of scores from the problem subscale of the Alcohol Use Disorder Identification Test (AUDIT items 4 to 10) in the UK Biobank [6]. Across both discovery GWAS, A/T, or C/G variants were excluded to avoid strand ambiguity. As we were focusing on AUD-associated variants shared between EA and AA, only variants having the same directions of effects in both EA-PAU and AA-AUD were included. Both GWAS summary statistics were downloaded from the database of genotypes and phenotypes (dbGaP: phs001672.v3.p1, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001672.v3.p1).

Target datasets

AA target datasets were drawn from 3 sources: the Collaborative Study on the Genetics of Alcoholism (COGA: N = 3375) [26], Study of Addiction: Genetics and Environment (SAGE: N = 930) [27], and YalePenn (N = 2010) [28]. COGA is a family cohort, in which alcohol-dependent probands and their family members from inpatient and outpatient alcohol dependence treatment facilities in seven sites were invited to participate. COGA also recruited community comparison families from a variety of sources in the same areas [26, 29]. The study was approved by Institutional review boards from all sites. Every participant provided informed consent. The Semi-Struc...
we noted earlier, AA is a very heterogeneous population. The three AA target datasets in this study were recruited under different ascertainment strategies and in different regions, therefore, meta-analyzed posterior effect sizes were used in this study. In addition, since we only focused on AUD-associated variants implicated in both AA and EA, meta-analysis posterior effect sizes should provide more accurate estimates for those variants. We first selected variants that had \( P < 0.05 \) in both EA-PAU and AA-AUD (i.e., at least showing marginal associations) and had the same directions of effects (referred to as concordant variants). For our gene-based PRS (PRSgene), only concordant variants located within gene boundaries (defined as within the region containing the gene plus 1 kb upstream of the transcription start site and 1 kb downstream of the transcription end site; annotated using ANNOVAR [45] based on NCBI RefSeq GRCh37) were used. To test whether using any concordant variants regardless of location would do as well, we calculated PRS using concordant variants located outside gene boundaries (referred to as PRSintergenic). We also tested whether further extending gene boundaries used to calculate PRSgene improved results by setting different window sizes: 10 kb, 25 kb, 50 kb, 100 kb, 250 kb, 500 kb, 1 Mb, 50 Mb, and 100 Mb. Lastly, we also used all variants across the entire genome to calculate PRS (PRSall) for comparison purposes. For all AA target datasets, PRSgene, PRSintergenic and PRSall were calculated using exactly the same sets of variants, respectively, thus they were directly comparable and can be combined. PLINK [37, 38] was used to calculate PRS using the posterior effect sizes estimated by PRS-Cx and imputation dosages. All PRS were standardized as mean = 0 and standard deviation = 1 in AA (all three datasets combined) and EA target datasets separately.

**Statistical analysis**

As COGA, SAGE, and YalePenn include related individuals, generalized linear mixed models were used with a random effect to adjust for family relationships. For Indiana Biobank, which is a cohort of unrelated individuals, logistic regression models were used. We also stratified individuals based on PRS deciles and compared each to the bottom decile. Since the sample sizes in COGA, SAGE, and YalePenn had insufficient sample sizes in each decile, we combined all three target datasets for the stratified analyses. For all models, sex and the top 10 PCs were included as covariates. For the combined analysis of COGA, SAGE, and YalePenn data, we also included the cohort indicator as an additional covariate. Associations with \( P < 0.05 \) were considered statistically significant for PRSgene, PRSintergenic, and PRSall, respectively.

**Gene enrichment analyses, searching GWAS catalog and potential drug target genes**

For genes included in calculating PRSgene, we performed gene ontology enrichment analysis using PANTHER (released 2021-01-24) [46] implemented in the Gene Ontology (GO) Resource (http://geneontology.org/, released 2021-08-18). We focused on GO Biological Processes (GOBPs). We also used Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) [47] to test whether these genes were enriched in Differentially Expressed Gene (DEG) sets calculated using 54 tissues from The Genotype-Tissue Expression (GTEx V8) project [48]. We searched the GWAS catalog (https://www.ebi.ac.uk/gwas/, accessed: 2021-10-11) [49] to check whether these genes had been previously implicated in GWAS of AUD-related phenotypes. Lastly, we checked whether these genes could be potential drug targets by searching the gene list for targets of the FDA-approved drugs as well as those in current clinical trial investigations, compiled by Wang et al. [24] derived from the Informa Pharmaprojects database (https://pharmaintelligence.ce.informa.com/products-and-services/data-and-analysis/pharma projects).

**RESULTS**

Samples used in this study are summarized in Table 1. In all target datasets, about 60% of cases were males while <42% of controls were males.

| Population | Target dataset | # case (%male) | # control (%male) | # total | # families |
|------------|----------------|----------------|-----------------|---------|-----------|
| AA         | All*           | 2786 (60.80)   | 3529 (39.27)    | 6315    | 3322      |
|            | COGA           | 875 (62.06)    | 2500 (41.60)    | 3375    | 590       |
|            | SAGE           | 387 (59.17)    | 543 (37.02)     | 930     | 869       |
|            | YalePenn       | 1524 (60.50)   | 486 (29.84)     | 2010    | 1863      |
| EA         | Indiana Biobank| 539 (62.15)    | 3515 (40.40)    | 4054    | 4054      |

*COGA, SAGE, and YalePenn combined.

PRS-Csx estimated posterior meta-analysis effect sizes for 1 126 428 variants and they were used to calculate PRSall. In total, there were 1 533 variants with \( P < 0.05 \) in both EA-PAU and AA-AUD and having the same directions of effects (i.e., concordant). Among them, 858 (Table S1) and 675 (Table S3) variants were located within (410 genes, Table S2) and outside gene boundaries, respectively. As shown in Table 2, for AA target datasets, both PRSgene and PRSall had \( P < 0.05 \) in all target datasets except PRSall for COGA. PRSintergenic had \( P > 0.10 \) in all target datasets, demonstrating that discordant variants located within genes better stratify risk for AUD than those located in intergenic regions. Effect sizes ranged from 0.15-0.21 for PRSgene, 0.02 to 0.12 for PRSintergenic, and 0.06-0.18 for PRSall respectively. In EA, 847 of 858 variants (Table S1), and 1 061 130 of 1 126 428 variants were present in Indiana Biobank after QC; both PRSgene and PRSall had \( P < 0.05 \) (PRSgene Beta=0.11, SE=0.02; PRSall Beta=0.34, SE=0.05) but not PRSintergenic (Beta = 0.02, SE = 0.05). Results of using different window sizes to extend gene boundaries are in Table S4 and Fig. S1. The numbers of variants increased slightly with larger window sizes, and windows 50 and 100 Mb had the same number of variants, indicating that most variants are located within or close to genes. Overall, the results were similar, therefore, we kept variants within gene boundaries because it was more straightforward to determine AUD genes, as larger distances often contained multiple genes, and it is challenging to assign intergenic variants to a gene.

The association between PRS and AUD increased from the bottom decile (1st decile) to the top decile (10th decile) (Fig. 1). Using the bottom decile as the reference group, all except the 2nd and 3rd deciles showed statistically significant association with the increased odds for AUD (ORs: 1.37–1.76, Table 3) after adjusting for covariates.

Of the 410 genes, 353 were uniquely mapped to the GO database. The unmapped genes were non-coding RNAs, antisense RNAs, pseudo-genomes, and read-throughs. Fifty-four GOBPs had false discovery rate (FDR) \( P < 0.05 \), including ethanol oxidation, synaptic signaling, synapse organization, synaptic plasticity, startle response, neurogenesis, nervous system development, learning or memory, protein metabolic process, cell adhesion, cell development, cell junction organization, movement of cell or subcellular component, cell-cell signaling, regulation of signaling, etc. (Table S5). Three hundred and seventy-four genes were targets of AUD-related phenotypes (Table S2). Twenty-six genes were targets of...
drugs approved by the FDA or in clinical trials. Among them, four (DRD2, PDE4B, GRM5, and SLC6A9) were drug target genes for AUD treatment (Table S6); for those 22 genes that were targets of drugs to treat diseases other than AUD, 21 were involved in the significant GOBPs identified and five (EIF4E, ESR1, MAPT, METAP1, and TNKS) were reported by previous GWAS of AUD-related phenotypes (Table S2).

**DISCUSSION**

In this study, we found that gene-based PRS (PRSgene) calculated using 858 variants from 410 genes were significantly associated with AUD in both AA and EA, and outperformed the PRS calculated using all variants (PRSall) in AA. Compared to the bottom decile, those at the top PRSgene decile were nearly twice as likely to be AUD cases (OR = 1.76) in AA. The 410 genes included in calculating PRSgene were enriched in 54 GOBPs, and many of them are likely to be AUD-related. They were also enriched in brain tissues. In addition, four genes were targets of drugs in Phase II or III clinical trials to treat AUD; 22 genes were targets of drugs approved by the FDA or in clinical trials. Among them, four (DRD2, PDE4B, GRM5, and SLC6A9) were drug target genes for AUD treatment (Table S6); for those 22 genes that were targets of drugs to treat diseases other than AUD, 21 were involved in the significant GOBPs identified and five (EIF4E, ESR1, MAPT, METAP1, and TNKS) were reported by previous GWAS of AUD-related phenotypes (Table S2).

**Table 2.** Associations between AUD and PRSgene, PRSintergenic, and PRSall in AA and EA.

| Population | Target dataset | PRSgene | Beta | SE | P-value | # Variants | Beta | SE | P-value | # Variants | Beta | SE | P-value | # Variants |
|------------|----------------|----------|------|----|---------|------------|------|----|---------|------------|------|----|---------|------------|
| AA         | All            | 0.17     | 0.03 | 3.55E-08 | 858 | 0.03 | 0.32 | 675 | 0.11 | 0.03 | 9.42E-05 | 11,264,288 |
| AA         | COGA           | 0.15     | 0.04 | 9.67E-04 | 858 | 0.02 | 0.46 | 675 | 0.06 | 0.04 | 0.16 | 11,264,288 |
| AA         | SAGE           | 0.18     | 0.07 | 6.27E-03 | 858 | 0.12 | 0.10 | 675 | 0.18 | 0.07 | 0.01 | 11,264,288 |
| AA         | YalePenn       | 0.21     | 0.05 | 7.61E-05 | 858 | 0.12 | 0.06 | 675 | 0.02 | 0.06 | 2.35E-03 | 11,264,288 |
| EA         | Indiana Biobank | 0.11 | 0.05 | 0.02 | 847 | 0.02 | 0.59 | 666 | 0.02 | 0.59 | 666 | 0.02 | 0.59 | 666 |

Significant P-values are in bold.

**Table 3.** Odds ratios when comparing each PRSgene decile with the bottom decile in AA (COGA, SAGE, and YalePenn combined).

| Decile | OR    | 95%CI     | P-value |
|--------|-------|-----------|---------|
| 10     | 1.76  | 1.32–2.34 | 1.03E–04|
| 9      | 1.72  | 1.29–2.29 | 2.05E–04|
| 8      | 1.52  | 1.15–2.00 | 2.93E–03|
| 7      | 1.64  | 1.27–2.12 | 1.49E–04|
| 6      | 1.43  | 1.09–1.87 | 0.01    |
| 5      | 1.37  | 1.05–1.79 | 0.02    |
| 4      | 1.48  | 1.13–1.93 | 4.55E–03|
| 3      | 1.22  | 0.91–1.62 | 0.18    |
| 2      | 1.11  | 0.85–1.45 | 0.44    |

Significant P-values are in bold.
leveraging methods that focus on intragenic signals with concordant directions of effects across ancestries. Furthermore, the process identified drugs already under development that could be evaluated for their potential to treat AUD.

To improve the performance of PRS, more disease-associated variants should be included and unrelated variants should be excluded. AUD is caused by many genes with small effects and in GWAS of AUD, due to the large number of variants tested, many variants that are unrelated to AUD show some degree of association (e.g., P-values < 0.05) purely by chance (i.e., false positives). If sample sizes are large (e.g., hundreds of thousands of participants or more), while the majority of AUD-associated variants are still not genome-wide significant, they usually have smaller P-values than those false positives and can still contribute to the calculation of PRS. However, when the discovery GWAS sample sizes are small to moderate, the discrimination between AUD-related and unrelated variants narrow. This leads to a reduction in PRS performance. Using large-scale EA discovery GWAS could mitigate this problem, but the improvement is limited even with sophisticated statistical methods due to the differences between the discovery GWAS and the target datasets [23]. Our gene-based PRS framework leverages the concordant variants across different populations and discriminates variants unrelated to the disease of interest leading to the improved performance of PRS. Using concordant variants also reduces the chance of selecting the wrong independent index variants due to a mismatch of LD patterns among the discovery and target datasets, as well as the external LD reference panels. Moreover, as PRSintergene were not associated with AUD in our analyses, the performance of PRSgene was further improved by focusing on concordant variants within gene boundaries. RRSgene had superior performance in all our AA target datasets, thus, we conclude that this strategy can be used to improve the performance of PRS when the discovery GWAS sample sizes are not sufficiently large, notable in admixture populations, and other groups that have been underrepresented in GWAS studies to date.

While PRSgene outperformed PRSintergene in AA, the opposite was observed in EA. This was expected for the following reasons. First, many GWAS findings, such as variants in KLB and GCKR, which reached genome-wide significance in EA, had P-values > 0.05 in AA (i.e., these genes may not be AUD-related in AA for some unknown mechanisms, or variants acting on these genes in AA have not been identified), therefore, they were not included in calculating PRSgene but were used in calculating PRSintergene in EA. Second, even within genes that have shown associations with AUD in both AA and EA, different causal variants may have been important in each ancestral group. One example is rs2066702 in the ADH1B gene. While relatively common in AA individuals (MAF = 0.18), the variant is rare in EA individuals (MAF = 0.002) (https://www.ncbi.nlm.nih.gov/snp/rs2066702?vertical_tab=true#frequency_tab). This was the only variant selected in ADH1B in calculating PRSgene, resulting in no contribution of ADH1B when calculating PRSgene in EA individuals from the Indiana Biobank. However, for PRSintergene, multiple common EA variants in ADH1B (e.g., rs2066701, rs10442026, and rs2075633) were included, thus increasing the performance of PRSintergene. Third, we limited inclusion to variants within gene boundaries. Although PRSintergene and PRSgene with extended boundaries analyses showed that overall including intergenic concordant variants did not increase the PRS performance, however, some AUD variants are not located within gene boundaries and this may affect AA and EA disproportionately. For example, rs1229978, which is located between ADH1B and ADH1C, is much more common in EA (MAF = 0.39) than in AA (MAF = 0.15) (https://www.ncbi.nlm.nih.gov/snp/rs1229978?vertical_tab=true); therefore, not including this variant in PRS calculations had a larger impact in EA than in AA. Nevertheless, the significance of PRSgene in both AA and EA suggested that most of these genes were AUD-related in these two populations.

More than half of the 410 genes (244) were involved in 54 significant GOBPs. As expected, ethanol oxidation was among them and four genes (ADH1B, ADH1C, ADH4, and ADH5) were involved. Compromised executive functioning (i.e., neuroadaptation) is one of the major mechanisms contributing to AUD [50] and not surprisingly, several significant GOBPs related to synaptic systems (synaptic signaling, synapse organization, synaptic plasticity, startle response) were identified (46 genes). Although the role of the synaptic system in AUD is well-established [50], however, only nine genes (CSMD1, DCC, DRD3, EIF4E, ERC2, LING02, MAPT, NRXN2, and TENM2) were implicated in previous GWAS of AUD-related phenotypes. We also found significant GOBPs related to learning and memory (27 genes), consistent with previous findings that AUD and neurodegenerative diseases share some genetic liability [51]. Nervous system development-related GOBPs were significant (69 genes), and genes involved may predispose to AUD via mechanisms yet to be discovered. GOBPs such as protein metabolic process, cell adhesion, cell development, cell junction organization, movement of cell or subcellular component, cell-cell signaling, and regulation of signaling were also significant. Intuitively, these GOBPs may not seem to be AUD-related, however, among 148 genes only involved in these processes, 20 of them were reported in previous GWAS of AUD-related phenotypes with some of them, e.g., FTO, PDE4B, and SLC39A8, being genome-wide significant in recent large-scale GWAS of AUD [7]. In addition, there were seven genes (EHHQ1, EYS, FNBQ4, LOC100507053, TNRC6A, WDR7, and ZNF462) that were not involved in any significant GOBPs but were reported by previous GWAS of AUD-related phenotypes. Further studies are needed to elucidate the roles of these genes in predisposing to AUD. Tissue-specific enrichment showed that most genes were enriched in brain tissues as expected, however, other tissues such as liver, kidney, and pancreas also showed enrichment. Except liver, how these tissues relate to AUD remain to be discovered. By searching the drug target gene database, we found four genes (DRD2, PDE4B, GRM5, and SLC6A9) were already targets of AUD treatment drugs (Table S6). We also found 22 genes that were targets of drugs to treat other diseases (Table S6) and could be examined and/or repurposed to treat AUD. Studies have found that gene-targeted drugs were more likely to get FDA approval [24, 52, 53], therefore, identifying the roles of genes used in calculating PRSgene could facilitate the development of novel treatment methods.

This study has several limitations. First, we limited to concordant variants in both AA and EA, thus, variants that may have discordant but true effects were excluded, reducing the performance of PRSgene. Second, although most intergenic concordant variants did not contribute to the PRS signal as shown in the analyses of PRSintergene and extended gene boundaries with different window sizes, some of them are truly AUD related and contribute to the risk of AUD, and excluding them leading to a further reduction in the performance of PRSgene. Third, we used posterior effects estimated from the meta-analysis of AA-MVP and EA-PAU. As EA-PAU had a much larger sample size (>5 times of sample size of AA-MVP), more weight was put on effects estimated from the EA samples. Therefore, for those variants that had different sizes of effects between AA and EA, effects from the meta-analysis were biased toward the EA GWAS. Fourth, studies have shown that using functional annotations can improve the performance of PRS and increase the transferability of PRS between different populations [11, 54–56]. However, most of the available functional annotation databases were generated using European ancestry samples and were not related to AUD, therefore, those functional information were not used in this study, which may also reduce the performance of PRSgene.
In summary, we calculated PRS for evaluating AUD risk that worked cross populations based on our novel gene-based PRS framework. Not only our new framework outperformed the PRS calculated using all variants in AA, but also the genes included in calculating PRS showed enrichment for biological plausible processes and are potential targets for drug development, therefore, this novel framework demonstrates the utilities of PRS beyond disease risk evaluation to the identification of biological processes and drug targets, and shed light on the genetic mechanism of AUD.

REFERENCES

1. World Health Organization. Global status report on alcohol and health 2018: executive summary. Geneva: World Health Organization; 2018.

2. Heath AC, Martin NG. Genetic influences on alcohol-consumption patterns and problem drinking - results from the Australian Nh-and-Mrc Twin Panel Follow-up Survey. Ann NY Acad Sci. 1994;708:72–85.

3. Prescott CA, Kendler KS. Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psychiatry. 1999;156:34–40.

4. Verhulst B, Neale MC, Kendler KS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychol Med. 2015;45:1061–72.

5. Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019;10:4499.

6. Sanchez-Roige S, Palmer AA, Fontanillas P, Elson SL, Adams MJ, Howard DM, et al. Genome-wide association study meta-analysis of the alcohol use disorders identification test (AUDIT) in two population-based cohorts. Am J Psychiatry. 2019;176:107–18.

7. Zhou H, Sevalom JM, Sanchez-Roige S, Clarke TK, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020;23:809–18.

8. Lai D, Johnson EC, Colbert S, Pandey G, Chan G, Chan B, and others. Evaluating risk for alcohol use disorder: Polygenic risk scores and family history. Alcohol Clin Exp Res. 2022;46:374–83.

9. Dawson DA, Harford TC, Grant BF. Family history as a predictor of alcohol dependence. Alcohol Clin Exp Res. 1992;16:34–44.

10. Wang Y, Guo J, Ni G, Yang J, Visscher PM, Yengo L. Theoretical and empirical calculation of PRS showed enrichment for biological plausible processes and drug targets, and shed light on the genetic mechanism of AUD.
targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47:D1005–D12.
50. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–73.
51. Kapoor M, Chao MJ, Johnson EC, Novikova G, Lai D, Meyers JL, et al. Multi-omics integration analysis identifies novel genes for alcoholism with potential overlap with neurodegenerative diseases. Nat Commun. 2021;12:5071.
52. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15:e1008489.
53. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–60.
54. Hu Y, Lu Q, Powles R, Yao X, Yang C, Fang F, et al. Leveraging functional annotations in genetic risk prediction for human complex diseases. PLoS Comput Biol. 2017;13:e1005589.
55. Liang Y, Pividori M, Manichaikul A, Palmer AA, Cox NJ, Wheeler H, et al. Polygenic transcriptome risk scores improve polygenic risk scores across ancestries. bioRxiv. 2020;2020.11.12.373647.
56. Weissbrod O, Hormozdiari F, Benner C, Cui R, Ulirsch J, Gazal S, et al. Functionally informed fine-mapping and polygenic localization of complex trait heritability. Nat Genet. 2020;52:1355–63.

ACKNOWLEDGEMENTS
COGA: The Collaborative Study on the Genetics of Alcoholism (COGA), Principal Investigators B. Porjesz, V. Hesselbrock, T. Foroud; Scientific Director, A. Agrawal; Translational Director, D. Dick, includes eleven different centers: University of Connecticut (V. Hesselbrock); Indiana University (H.J. Edenberg, T. Foroud, Y. Liu, M.H. Flawuck); University of Iowa Carver College of Medicine (S. Kuperman, J. Kramer); SUNY Downstate Health Sciences University (B. Porjesz, J. Meyers, C. Kamarajan, A. Pandey); Washington University in St. Louis (L. Bierut, J. Rice, K. Bucholz, A. Agrawal); University of California at San Diego (M. Schuckit); Rutgers University (J. Tischfield, R. Hart, J. Salvatore); The Children's Hospital of Philadelphia, University of Pennsylvania (L. Almasy); Virginia Commonwealth University (D. Dick); Icahn School of Medicine at Mount Sinai (A. Goate, P. Slesinger); and Howard University (D. Scott). Other COGA collaborators include: L. Bauer (University of Connecticut); J. Nurnberger Jr., L. Wettenhill, X. Xuei, D. Lai, S. O'Connor (Indiana University); G. Chan (University of Iowa; University of Connecticut); D.B. Chorlian, J. Zhang, P. Barr, S. Kinceich, G. Pandey (SUNY Downstate); N. Mullins (Icahn School of Medicine at Mount Sinai); A. Anokhin, S. Hartz, E. Johnson, V. McCutcheon, S. Saccone (Washington University); J. Moore, Z. Pang, S. Kuo (Rutgers University); A. Merikangas (The Children's Hospital of Philadelphia and University of Pennsylvania); F. Aliev (Virginia Commonwealth University); H. Chin and A. Parisian are the NAAA Staff Collaborators. We continue to be inspired by our memories of Henri Begleiter and Theodore Reich, founding PI and Co-PI of COGA, and also owe a debt of gratitude to other past organizers of COGA, including Ting-Kai Li, P. Michael Conneally, Raymond Crowe, and Wendy Reich, for their critical contributions. This national collaborative study is supported by NIH Grant U10AA008401 from the National Institute on Alcohol Abuse and Alcoholism (NAAA) and the National Institute on Drug Abuse (NIDA). This study was made possible, in part, with support from the Indiana Clinical and Translational Sciences Institute funded, in part by Award Number UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award, and the National Center for Research Resources, Construction grant number RR020128 and the Lilly Endowment. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors acknowledge the Indiana University Pervasive Technology Institute for providing [HPC (Big Red II, Karst, Carbonate), visualization, database, storage, or consulting] resources that have contributed to the research results reported within this paper. AA acknowledges K02DA032573, R01DA054869.

AUTHOR CONTRIBUTIONS
DL designed the study, performed the analyses, and wrote the manuscript. DL, TS, and MA processed data. TS, MA, GC, VH, CK, YL, JLM, JIN, MHP, LW, MS, PZ, HJE, BP, AA, and TF contributed to the results interpretation and preparing the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-02029-2.

Correspondence and requests for materials should be addressed to Dongbing Lai.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022